MetLife Investment Management’s Abeona Therapeutics ABEO Stock Holding History

MetLife Investment Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$153K	Buy	24,766 +994	+4%	+$5.46K	﹤0.01%	2552
2026 Q1	$106K	Sell	23,772 -166	-0.7%	-$830	﹤0.01%	2510
2025 Q4	$126K	Sell	23,938 -2,688	-10%	-$13.5K	﹤0.01%	2496
2025 Q3	$141K	Hold	26,626	–	–	﹤0.01%	2496
2025 Q2	$151K	Buy	+26,626	New	+$152K	﹤0.01%	2333
2019 Q3	–	Sell	-503	Closed	-$60.1K	–	2330
2019 Q2	$60.1K	Sell	503 -1,006	-67%	-$169K	﹤0.01%	2410
2019 Q1	$278K	Buy	1,509 +1,006	+200%	+$180K	﹤0.01%	2300
2018 Q4	$89.8K	Hold	503	–	–	﹤0.01%	2317
2018 Q3	$161K	Sell	503 -270	-35%	-$95.8K	﹤0.01%	2200
2018 Q2	$309K	Buy	773 +283	+58%	+$124K	﹤0.01%	1701
2018 Q1	$176K	Hold	490	–	–	﹤0.01%	1950
2017 Q4	$194K	Buy	+490	New	+$203K	﹤0.01%	1942

Other funds holding ABEO

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's ABEO Position: Q2 2026 in Review

MetLife Investment Management increased its Abeona Therapeutics (ABEO) stake by 4.2% in Q2 2026, buying an estimated $5.46K and bringing the position to 24,766 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #2552.

MetLife Investment Management first reported a position in ABEO in Q4 2017 and has held it in 12 quarters since. The position peaked at $309K in Q2 2018. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

MetLife Investment Management held 24,766 shares of Abeona Therapeutics worth $153K as of Q2 2026.
MetLife Investment Management bought 994 Abeona Therapeutics shares in Q2 2026, an estimated $5.46K.
Abeona Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2552 holding.
MetLife Investment Management first reported a position in Abeona Therapeutics in Q4 2017 and has held it in 12 quarters since.
MetLife Investment Management's Abeona Therapeutics position peaked at $309K in Q2 2018.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.